Friday December 05 2008 | Biotechnology feed | All feeds
|
|
Friday December 05 2008 | Biotechnology feed | All feeds
|
|
| Agilent Technologies and Paradigm Genetics Launch Mouse Oligo Microarray to Aid in Drug Reaction Research Microarrays to be Used in Research by the NIEHS, Toxicogenomics Research Consortium BOSTON, Drug Discovery Technology 2003, Aug. 11, 2003 -- Agilent Technologies Inc. (NYSE: A) and Paradigm Genetics Inc. (NASDAQ: PDGM) today introduced a 60-mer oligonucelotide mouse microarray as part of a previously announced collaboration. The new Agilent Mouse Oligo Microarray Kit provides researchers the ability to conduct genome-wide profiling research to better understand adverse drug reactions, physiological effects of toxins and toxic substances, and to study genetic diseases such as cancer. The mouse oligo microarray can be used to assess over 20,000 well-characterized mouse genes and transcripts, including a special set of toxicology markers defined through collaboration with several public and private enterprises, including the National Institute of Environmental Health Sciences (NIEHS) and members of the Toxicogenomics Research Consortium. As part of its $23.8 million toxicogenomics contract with the NIEHS, Paradigm Genetics is beginning to process thousands of Agilent mouse and rat oligo microarrays to develop genetic profiles of organism responses to toxicants. Eventually, these profiles will be collected into a toxicogenomics database that will be publicly available to the scientific community for their research. Building on their expertise in DNA microarray processing and data analysis, Paradigm has developed a microarray research services business, using Agilent's gene expression platform and the Rosetta Resolver® system. "We've been working closely with Agilent and researchers in the field to produce a microarray that will further the research of the toxicogenomics program, and help promote convergence to an open standard microarray for toxicogenomics," said Heinrich Gugger, Ph.D., president and CEO of Paradigm Genetics. "The introduction of this microarray is an important milestone for our research. We are already processing the new Agilent Mouse Oligo Microarrays for the Toxicogenomics Research Consortium and the highly-sensitive, robust results speak for themselves." "This new mouse microarray serves as a complement to our Mouse Development Oligo Microarray Kit released last fall, which focused on developmental genes in mice," said Barney Saunders, vice president and general manager, Agilent BioResearch Solutions. "For both microarrays, we have worked with Paradigm Genetics and other leading researchers in the field to ensure that the best and most up-to-date genetic information is used. We believe this particular microarray will be of great value to gene expression researchers in the areas of toxicogenomics, cancer, immunology and neuroscience." Together, the Agilent Mouse Oligo Microarray Kit and Mouse Development Oligo Microarray Kit provide coverage of approximately 34,000 genes and transcripts. These microarrays are printed with 60-mer oligo probes on a 1" x 3" glass slide, making them accessible to any lab that has a standard 1" x 3" scanner or the Agilent Microarray Scanner. Researchers can also add their own novel probes to either of these microarrays through Agilent's Custom Microarray Services. Availability and More Information The Agilent Mouse Oligo Microarray Kit (G4121A) and Mouse Development Oligo Microarray Kit (G4120A) are available now. To order, visit the Agilent Web site at www.agilent.com/chem/mouse . To view gene lists, technical documentation and scientific literature regarding these microarrays and other Agilent gene expression products, visit www.agilent.com/chem/catalog . Additional information on Paradigm's DNA microarray services is available at www.paradigmgenetics.com/micro/ . About Paradigm Genetics Paradigm is a biotechnology company aiming to increase R&D productivity by focusing its integrated suite of technologies on the product development cycle, from target discovery to subsequent enhancement of the safety and efficacy profiles of development candidates in agriculture and human health. Paradigm chooses a systems biology approach to understand gene function in the context of biological pathways, to develop assays and biomarkers for molecular diagnostic solutions tailored to the needs of our partners. For more information, visit www.paradigmgenetics.com. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company's 32,000 employees serve customers in more than 110 countries. Agilent had net revenue of $6 billion in fiscal year 2002. Information about Agilent is available on the Web at www.agilent.com. # # # Rosetta Resolver is a U.S. trademark of Rosetta Inpharmatics. NOTE TO EDITORS: Press releases, photography and other information can be accessed on the Agilent Life Sciences and Chemical Analysis newsroom at www.agilent.com/about/newsroom/lsca . Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news . ------------------------------------ Victor Truong Press Relations Associate Life Science & Chemical Analysis Agilent Technologies, Inc. 5301 Stevens Creek Blvd. Mailstop-53U-WQ Santa Clara, CA 95052-8059 +1 408 553-7113 Tel +1 408 553-7284 Fax www.agilent.com U.S. CONTACT: Christina Maehr, Agilent Technologies, +1 408 553 7205,
christina_maehr@agilent.com |
|
|
